PreciThera, Inc. Completes $36 Million Series A Financing

PreciThera, Inc. Completes $36 Million Series A Financing

MONTREAL, July 27, 2017 – PreciThera, Inc. a privately-held, precision medicine company, dedicated to the design and development of innovative biological therapeutics for the treatment of orphan bone diseases, today announced the completion of a Series A Financing of CAD$36 million (US$29 million). Investors participating in the financing include Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital.

No Comments

Post A Comment